Stock Price Movement and Market Context
On 2 Feb 2026, Vivo Bio Tech Ltd. saw its share price fall sharply to an intraday low of Rs.25.2, representing an 11.39% drop from previous levels. This decline followed three consecutive days of gains, signalling a reversal in short-term momentum. The stock underperformed its sector by 4.31% on the day, highlighting relative weakness within the Pharmaceuticals & Biotechnology space.
Volatility was elevated, with an intraday weighted average price volatility of 6.73%, underscoring the unsettled trading conditions. Additionally, the stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a sustained bearish trend across multiple time horizons.
The broader market context was also subdued. The Sensex opened 167.26 points lower and was trading at 80,490.50, down 0.29%. Notably, other indices such as the S&P BSE FMCG and NIFTY FMCG also hit new 52-week lows on the same day, reflecting sector-specific pressures. The Sensex itself is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, suggesting some underlying longer-term support for the benchmark.
Long-Term Performance and Valuation Metrics
Over the past year, Vivo Bio Tech Ltd. has delivered a negative return of 38.83%, significantly underperforming the Sensex, which posted a positive 3.87% return over the same period. The stock’s 52-week high was Rs.46.75, indicating a steep decline of nearly 46% from its peak.
From a fundamental perspective, the company’s long-term growth has been subdued, with a compound annual growth rate (CAGR) in net sales of -0.84% over the last five years. Profitability metrics also remain modest, with an average return on equity (ROE) of 6.60%, signalling limited earnings generation relative to shareholders’ funds.
The company’s ability to service debt is constrained, as reflected by a low EBIT to interest coverage ratio averaging 1.84, which points to limited buffer for interest obligations. The return on capital employed (ROCE) for the half year ended September 2025 was 7.95%, among the lowest in recent periods, further highlighting challenges in generating efficient returns on invested capital.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Recent Financial Results and Operational Indicators
The company’s recent financial results have shown subdued growth. The profit after tax (PAT) for the nine months ended September 2025 stood at Rs.3.27 crores, reflecting a decline of 46.74% compared to the prior period. This contraction in profitability aligns with the stock’s downward trajectory.
Further, the debtor turnover ratio for the half year was 3.54 times, one of the lowest levels recorded, indicating slower collection cycles and potential working capital pressures. These factors contribute to the cautious sentiment surrounding the stock’s near-term prospects.
In terms of valuation, Vivo Bio Tech Ltd. presents a very attractive enterprise value to capital employed (EV/CE) ratio of 0.8, suggesting the stock is trading at a discount relative to its capital base. This valuation is lower than the average historical valuations of its peers, reflecting the market’s tempered outlook on the company’s growth and profitability potential.
Comparative Performance and Shareholding Pattern
Vivo Bio Tech Ltd. has underperformed not only the Sensex but also the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in delivering shareholder returns. The stock’s Mojo Score stands at 26.0, with a Mojo Grade of Strong Sell as of 19 Jan 2026, an upgrade from the previous Sell rating, signalling continued caution.
The company’s market capitalisation grade is 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics.
Is Vivo Bio Tech Ltd. your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Metrics
To summarise, Vivo Bio Tech Ltd. is currently trading at Rs.25.2, its lowest level in 52 weeks, down from a high of Rs.46.75. The stock’s one-year return is -38.83%, contrasting with the Sensex’s positive 3.87% over the same period. The company’s financial indicators reveal subdued sales growth, declining profits, and modest returns on equity and capital employed. Debt servicing capacity remains limited, and recent operational metrics such as debtor turnover have weakened.
Despite these challenges, the stock’s valuation metrics suggest it is trading at a discount relative to peers, with an EV/CE ratio of 0.8 and a ROCE of 7.8%. However, the overall market sentiment and technical indicators continue to reflect a cautious stance.
Market Outlook and Technical Positioning
Technically, the stock’s position below all major moving averages indicates a sustained downtrend. The recent volatility and sharp intraday declines reinforce the prevailing bearish momentum. The broader market’s mixed performance, with some indices also hitting 52-week lows, adds to the challenging environment for Vivo Bio Tech Ltd.
Investors and market participants will likely continue to monitor the company’s financial performance and sector developments closely as the stock navigates this low price territory.
Unlock special upgrade rates for a limited period. Start Saving Now →
